{
    "clinical_study": {
        "@rank": "126099", 
        "arm_group": [
            {
                "arm_group_label": "0.25 mg VPD-737", 
                "arm_group_type": "Experimental", 
                "description": "0.25 mg of VPD-737 daily by mouth for 42 days"
            }, 
            {
                "arm_group_label": "1 mg VPD-737", 
                "arm_group_type": "Experimental", 
                "description": "1 mg VPD-737 taken daily by mouth for 42 days"
            }, 
            {
                "arm_group_label": "5 mg VPD-737", 
                "arm_group_type": "Experimental", 
                "description": "5 mg tablets of VPD-737 to be taken daily by mouth for 42 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo tablets to be taken daily by mouth for 42 days"
            }
        ], 
        "brief_summary": {
            "textblock": "A study of a several doses of a novel treatment for chronic itch compared to placebo   for\n      patients whose condition has not responded to other treatments"
        }, 
        "brief_title": "VPD-737 for Treatment of Chronic Pruritus", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Pruritus", 
        "condition_browse": {
            "mesh_term": "Pruritus"
        }, 
        "detailed_description": {
            "textblock": "The sensation of itch is transmitted to the brain through the nervous system   Several\n      chemicals are involved in transmitting this signal   This trial of VPD 737 is intended to\n      treat this condition by blocking one of the chemicals involved in the transmission of the\n      itch signal  This is an oral drug administered once daily  It has been used in other trials\n      and has shown to be safe at the doses used in this trial   The trial will involve once daily\n      pills for 6 weeks.   Subject will be asked to fill out questionnaires both electronically\n      and on paper during the study period   Patients will also be monitored for safety and will\n      have blood taken for testing and several points during the trial   Overall participation\n      will last about 12 weeks"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of chronic pruritus and unresponsive to current therapies\n\n        Exclusion Criteria:\n\n          -  Have chronic liver or renal disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951274", 
            "org_study_id": "TCP 101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.25 mg VPD-737", 
                    "1 mg VPD-737", 
                    "5 mg VPD-737"
                ], 
                "description": "NK1 Receptor Antagonist", 
                "intervention_name": "VPD-737", 
                "intervention_type": "Drug", 
                "other_name": "Serlopitant"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77056"
                }, 
                "name": "Suzanne Bruce and Associates, P.A."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus", 
        "overall_contact": {
            "last_name": "Michael Dunn", 
            "phone": "201-587-0500", 
            "phone_ext": "3391"
        }, 
        "overall_official": {
            "affiliation": "Acting Chief Medical Officer, Tigercat Pharma, Inc.", 
            "last_name": "Edward F Schnipper, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Visual Analog Scale", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951274"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Verbal Response Scale", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "Tigercat Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tigercat Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}